Multiply-resistant Pseudomonas aeruginosa were first detected in north-east
ern Germany at the end of 1996; since then they have been isolated predomin
antly from patients in intensive care units. Colonization/infection, especi
ally of the respiratory tract, has been demonstrated in 80 patients, with s
trains resistant to beta-lactams, carbapenems, aminoglycosides and quinolon
es. Amikacin showed in-vitro synergy with cefepime, ceftazidime or piperaci
llin/tazobactam. Horizontal transfer of strains was followed by PFGE and id
entical strains were detected in the environment, but the source of infecti
on was not established. Rigorous infection control and restricted clinical
use of carbapenems limited further dissemination of this outbreak.